Abstract:•What is already known about this subject•Ammoxetine is a novel selective serotonin and norepinephrine reuptake inhibitor with potential utility for therapy in major depressive disorder.•Pre-clinical studies in animal depression models indicated ammoxetine produces potent inhibition of 5-HT and NE reuptake and results in a robust antidepressant activity.•What this study adds•This first-in-human study provided the initial safety, tolerability and pharmacokinetic profiles of ammoxetine in healthy subjects.•The study investigated the effect of CYP2C19 polymorphisms on the metabolism of ammoxetine.•The favorable safety, tolerability and the linear pharmacokinetic profile of ammoxetine were observed, which could enable dose selections and further clinical development in subsequent studies in patients with major depressive disorder.

First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study